Hemophilia A - Epidemiology Forecast – 2030

Hemophilia A - Epidemiology Forecast – 2030

  • January 2021 •
  • 125 pages •
  • Report ID: 6025290 •
  • Format: PDF
‘Hemophilia A - Epidemiology Forecast to 2030’ report delivers an in-depth understanding of the disease, historical and forecasted Hemophilia A epidemiology in the 7MM, i.e., the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
Hemophilia A Understanding
Hemophilia is a general term for a group of rare bleeding disorders caused by a congenital deficiency of certain clotting factors. The main form of hemophilia is hemophilia A; it is different from hemophilia B. The main difference between them is that hemophilia B is associated with a deficiency in factor IX (9) while hemophilia A is associated with deficiency of factor VIII (8). About 80% of people with hemophilia have hemophilia A. It is worth noting that, about 30% of severe hemophilia A patients develop neutralizing anti-FVIII alloantibodies (inhibitors), which render the FVIII replacement ineffective. According to the CDC (Centers for Disease Control and Prevention), screening tests and clotting factor tests are involved in the diagnosis. Blood tests that show if the blood is clotting properly are screening tests. In order to diagnose a bleeding disorder, clotting factor tests, also called factor assays, are required. The type of hemophilia and the severity are shown by this blood test.

Epidemiology Perspective
The Hemophilia A epidemiology division provides the insights about historical and current Hemophilia A patient pool and forecasted trend for each seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

Key Findings
The overall prevalent cases of Hemophilia A in 2020 are projected to be around 43,243 in the 7MM that are expected to grow during the study period, i.e., 2018–2030.
The disease epidemiology covered in the report provides historical as well as forecasted Hemophilia A epidemiology [segmented as Total diagnosed Prevalent Pool of Hemophilia A, Severity-specific diagnosed Prevalent Pool of Hemophilia A, Inhibitor-specific Prevalent Pool of Hemophilia A and Total Treated Cases of Hemophilia A] scenario of Hemophilia A in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and United Kingdom), and Japan from 2020 to 2030.

Country Wise- Hemophilia A Epidemiology
• In the United States, the total number of prevalent cases of Hemophilia A was 14,630 cases in the year 2020 which are expected to grow during the study period, i.e., 2018–2030.
• In the year 2020, the total prevalent cases of Hemophilia A were 23,284 cases in EU-5 which are expected to grow during the study period, i.e., 2018–2030.
• In Japan, the total number of prevalent cases of Hemophilia A was 5,329 cases in the year 2020 which are expected to grow during the study period, i.e., 2018–2030.
• Severe Hemophilia A cases are more prominent in comparison to mild and moderate. Additionally, moderate and severe accounts for 75% of the Hemophilia A patient pool.
• In the 7MM, approximately 30% of severe hemophilia A cases develop inhibitors, i.e., 6,422 patients with inhibitors in 2020. In addition to this, 70% of the Hemophilia A cases were observed without inhibitors. The number of cases for both categories will increase during the study period.

Scope of the Report
• The Hemophilia A report covers a detailed overview explaining its causes, symptoms, and pathophysiology, diagnosis, and treatment patterns.
• The Hemophilia A Report and Model provide an overview of the risk factors and global trends of Hemophilia A in the seven major markets (7MM: United States, Germany, France, Italy, Spain, and the United Kingdom, and Japan)
• The report provides insight about the historical and forecasted patient pool of Hemophilia A in seven major markets covering the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
• The report helps to recognize the growth opportunities in the 7MM with respect to the patient population.
• The report assesses the disease risk and burden and highlights the unmet needs of Hemophilia A.
• The report provides the segmentation of the Hemophilia A epidemiology by diagnosed prevalent cases in the 7MM.
• The report provides the segmentation of the Hemophilia A epidemiology by severity-specific cases of Hemophilia A in the 7MM.
• The report provides the segmentation of the Hemophilia A epidemiology by with inhibitor and without inhibitor-specific cases of Hemophilia A in the 7MM.
• The report provides the segmentation of the Hemophilia A epidemiology by treated cases of Hemophilia A in the 7MM.

Report Highlights

• 10-Year Forecast of Hemophilia A epidemiology
• 7MM Coverage
• Total diagnosed Prevalent Pool of Hemophilia A
• Severity-specific diagnosed Prevalent Pool of Hemophilia A
• Inhibitor-specific Prevalent Pool of Hemophilia A
• Total Treated Cases of Hemophilia A
KOL-Views
We interview, KOL’s and SME’s opinion through primary research to fill the data gaps and validate our secondary research. The opinion helps to understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the over Hemophilia A scenario of the indications.

Key Questions Answered
• What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Hemophilia A?
• What are the key findings pertaining to the Hemophilia A epidemiology across the 7MM and which country will have the highest number of patients during the study period (2018–2030)?
• What would be the total number of patients of Hemophilia A across the 7MM during the study period (2018–2030)?
• Among the EU5 countries, which country will have the highest number of patients during the study period (2018–2030)?
• At what CAGR the patient population is expected to grow in the 7MM during the study period (2018–2030)?
• What are the various recent and upcoming events which are expected to improve the diagnosis of Hemophilia A?

Reasons to buy
The Hemophilia A Epidemiology report will allow the user to -
• Develop business strategies by understanding the trends shaping and driving the global Hemophilia A market
• Quantify patient populations in the global Hemophilia A market to improve product design, pricing, and launch plans
• Organize sales and marketing efforts by identifying the age groups and gender that present the best opportunities for Hemophilia A therapeutics in each of the markets covered
• Understand the magnitude of Hemophilia A population by its severity
• The Hemophilia A epidemiology report and model were written and developed by Masters and PhD level epidemiologists
• The Hemophilia A Epidemiology Model developed is easy to navigate, interactive with dashboards, and epidemiology based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over 10-year forecast period using reputable sources

Key Assessments
• Patient Segmentation
• Disease Risk and Burden
• Risk of disease by the segmentation
• Factors driving growth in a specific patient population

Geographies Covered
• The United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan
Study Period: 2018–2030